Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. November 2021 08:00 ET | Quelle: Virion Therapeutics, LLC

Virion Therapeutics, LLC Announces the Appointment of Sue Currie, Ph.D. as Chief Operating Officer

Philadelphia PA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Virion Therapeutics, LLC, developer of immunotherapies for cancer and chronic infectious diseases that utilize genetically encoded checkpoint...
12. Juli 2021 08:00 ET | Quelle: Virion Therapeutics, LLC

Virion Therapeutics, LLC Announces the Appointment of M. Michelle Berrey, M.D., M.P.H. and Williamson Bradford, M.D., Ph.D. to Its Board of Directors

Philadelphia PA, July 12, 2021 (GLOBE NEWSWIRE) -- Virion Therapeutics, LLC, developer of T cell-based immunotherapies that utilize the first genetically encoded checkpoint inhibitor today...
25. Juni 2021 09:00 ET | Quelle: Virion Therapeutics, LLC

Virion Therapeutics Presents Data Showing Enhanced and Sustained Virus Declines in Animals upon Immunization with VRON-0200, a Therapeutic Vaccine for Chronic Hepatitis B Virus (HBV) Infections at the International Liver Congress (ILC)

Philadelphia PA, June 25, 2021 (GLOBE NEWSWIRE) -- Virion Therapeutics, LLC, developer of T cell-based immunotherapies that utilize the first genetically encoded checkpoint inhibitor, today...
21. Juni 2021 08:00 ET | Quelle: Virion Therapeutics, LLC

Virion Therapeutics Announces Presentation of Preclinical Data of VRON-0200, a Chronic Hepatitis B Virus (HBV) Therapeutic Vaccine, at the International Liver Congress (ILC)

Philadelphia PA, June 21, 2021 (GLOBE NEWSWIRE) -- Virion Therapeutics, LLC, developers of T cell-based immunotherapies that utilize the first genetically encoded checkpoint inhibitor, today...